KRAS and colorectal carcinoma: Here, we demonstrate that KRAS mutation in CRC suppressed the activation of AMPK to stimulate the translation of myeloid cell leukemia 1 (Mcl-1) via the activation of the mammalian target of rapamycin (mTOR) pathway.